News Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7048 ^USD	+5.37%		+3.42%	-2.11%

Mar. 08	Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	Dec. 21	MT
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis	Dec. 21	AQ
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	Dec. 21	CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)	23-10-23	PU
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial	23-10-23	AQ
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23-10-23	CI
HC Wainwright Downgrades Galecto to Neutral From Buy	23-09-28	MT
Galecto Announces Plans to Explore Strategic Alternatives	23-09-26	CI
Galecto to Explore Strategic Options, to Reduce Workforce	23-09-26	MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	23-09-26	CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	23-09-26	CI
Galecto Announces Plans to Explore Strategic Alternatives	23-09-26	AQ
Galecto to Present at Investor Conferences in September	23-08-31	AQ
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	23-08-21	MT
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	23-08-15	MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon	23-08-15	MT
Top Midday Decliners	23-08-15	MT
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall	23-08-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Galecto, Inc.

Equities

GLTO

US36322Q1076

Summary

Filters